[1] |
YANG Ziyi, LI Panli, GU Bingxin, LIU Cheng, SONG Shaoli, XU Xiaoping.
The synthesis of a novel molecular imaging probe 68Ga-DOTA-PDL1P and application in mouse model of melanoma
[J]. China Oncology, 2023, 33(4): 354-360.
|
[2] |
TIAN Xi, XU Wenhao, ZHU Shuxuan, AIHETAIMUJIANG•Anwaier, SU Jiaqi, YE Shiqi, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei.
Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022
[J]. China Oncology, 2023, 33(3): 191-200.
|
[3] |
FU Qingsheng, JIN Lei, ZHANG Xudong, XU Yingchen, ZHU Chunfu, QIN Xihu, WU Baoqiang.
Effect of tRF-Pro-CGG on the biological behavior of mouse pancreatic cancer cells and its molecular mechanism
[J]. China Oncology, 2023, 33(3): 241-249.
|
[4] |
SU Jiaqi, XU Wenhao, TIAN Xi, ANWAIE Aihetaimujiang, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei.
New strategies for combined with immunotherapy of clear cell renal cell carcinoma: advances in aerobic glycolysis
[J]. China Oncology, 2022, 32(4): 287-297.
|
[5] |
MA Guang, OU Xiaomin, HU Chaosu, SONG Shaoli, YANG Zhongyi.
Value of pretreatment 18F-FLT PET/CT and 18F-FDG PET/CT uptake heterogeneity for early prediction of treatment outcome in locally advanced nasopharyngeal carcinoma
[J]. China Oncology, 2022, 32(4): 309-315.
|
[6] |
CAO Dalong, YE Dingwei.
New trends and future prospects of regulatory cell death in renal carcinoma
[J]. China Oncology, 2022, 32(10): 1000-1006.
|
[7] |
LEI Kunyang, XIE Wenjie, SUN Ting, LIU Yifu, WANG Xu.
Expression and effect of long non-coding RNA ARAP1-AS1 in clear cell renal cell carcinoma
[J]. China Oncology, 2022, 32(1): 34-40.
|
[8] |
YANG Bao , WANG Jing , CHEN Chao , ZHOU Jie , LI Hai .
A study on the tumorigenic effect of HIF-1α on human colorectal cancer cells in nude mice
[J]. China Oncology, 2021, 31(5): 377-382.
|
[9] |
TONG Ying, YU Yiwen, XIE Suhong, WANG Yanchun, LU Renquan, GUO Lin.
Effects of silent information regulator 4 overexpression or glutamine deprivation on apoptosis and proliferation of clear cell renal cell carcinoma
[J]. China Oncology, 2020, 30(6): 435-440.
|
[10] |
LI Zeng, LIAO Hong, MAO Dun, WU Yi, XIAO Yingming, YANG Shengke, ZHONG Lei, ZHOU Shukui, CHEN Yongji.
The value of 18 F-PSMA-1007 PET/CT in accurate assessment of newly diagnosed prostate cancer and its impact on clinical treatment decisions
[J]. China Oncology, 2020, 30(3): 231-236.
|
[11] |
TIAN Xi, XU Wenhao, QU Yuanyuan, WANG Jun, WANG Hongkai, CAO Dalong, SHI Guohai, ZHANG Hailiang, YE Dingwei.
Clinical features of renal cell carcinoma carrying second primary estrogen-related tumors: propensity score matching analysis
[J]. China Oncology, 2019, 29(12): 941-947.
|
[12] |
REN Wenjia , ZHOU Min , WU Shixiu , CHEN Junqiang , CHEN Yanan , CHEN Weiwei , AI Tashan , CHEN Yun , JIANG Guoliang , ZHAO Kuaile .
Prognostic and predictive value of 18 F-FLT PET/CT in patients with esophageal squamous carcinoma treated by radiochemotherapy
[J]. China Oncology, 2019, 29(12): 965-970.
|
[13] |
XU Mingbin, ZHAO Yutong, LI Chengyang, ZHAO Jiawen, MA Chenjun, LIAO Naikai, YANG Zhanbin, CHENG Jiwen.
Predictive value of lymphocyte-to-monocyte ratio and serum albumin in patients with clear cell renal cell carcinoma
[J]. China Oncology, 2019, 29(11): 887-898.
|
[14] |
ZHENG Yingying,XU Junyan,ZHANG Jianping, et al.
The value of 18F-FDG PET/CT texture analysis in predicting neoadjuvant chemoradiotherapy of locally advanced rectal cancer
[J]. China Oncology, 2018, 28(8): 590-594.
|
[15] |
ZHANG Yingqiang, ZHANG Xin, WANG Chen, et al.
The value of 18F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy
[J]. China Oncology, 2018, 28(7): 505-510.
|